Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 33.3%High 3 · 50%

Hydrocortisone (systemic corticosteroid) vs Placebo or no treatment

Outcome not reported · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
Table 1: 'Studies of these corticosteroids were not found or included in the review but are included here for completeness.' No trial of hydrocortisone for RAS was identified.
0 studies
No studies found

Systemic corticosteroids vs placebo or control

Mortality Mortality at latest · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
RR 0.81 [0.66, 0.99]
21 studies · 1428 participants
High

Systemic corticosteroids vs placebo or control

Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
RR 0.89 [0.8, 0.99]
14 studies · 988 participants
Moderate

Systemic corticosteroids vs placebo or control

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
RR 0.85 [0.79, 0.92]
14 studies · 988 participants
Moderate

Systemic corticosteroids vs placebo or control

Cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
RR 1.17 [0.84, 1.61]
17 studies · 1290 participants
High

Systemic corticosteroids vs placebo or control

Death or cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants 2021 · Cochrane Headline outcomes only
RR 0.9 [0.76, 1.06]
17 studies · 1290 participants
High